Pulmonary fate of [3H]bleomycin A2 in mice

JS Lazo and ET Pham

The pulmonary fate of radiolabeled bleomycin [S-methyl-3H]bleomycin A2 ( [3H]BLM A2) was studied in mice after intratracheal (i.t.) or s.c. injection. The loss of radioactivity from the lungs followed apparent first-order kinetics during the first 3 hr after i.t. drug instillation with a half-time of removal of 32 min. In addition, the initial pulmonary removal was linear with instilled doses ranging from 0.02 to 2.2 mg/kg. Radioactivity was detected in liver, kidneys, spleen and serum 1 hr after i.t. administration. Approximately 1% of the i.t. administered dose was detected in the lungs after 24 hr, indicating that the rate of removal of radioactivity slowed between 3 and 24 hr after i.t. drug instillation. Eighty percent of the radioactivity found in the lungs 1 hr after i.t. instillation was unmetabolized [3H]BLM A2, but by 24 hr less than 25% was unmetabolized drug and almost 40% was the nonfibrogenic metabolite, desamidobleomycin A2. After s.c. administration of 10 mg/kg of [3H]BLM A2, peak pulmonary levels were observed between 45 and 60 min and were less than 1% of the injected dose. Pulmonary levels comparable to those seen with a single fibrogenic i.t. dose (2.2 mg/kg) could not be obtained after a s.c. injection even with a toxic dose of the drug (100 mg/kg). In addition, twice weekly s.c. injections of unlabeled BLM A2 (10 mg/kg) for 5 weeks did not alter the amount of radioactivity seen in the lungs after a s.c. injection of [3H]BLM A2. Thus, the pulmonary fibrosis seen with i.t. BLM administration may reflect the high initial content of unmetabolized drug achieved in the lungs.

Volume 228, Issue 1, pp. 13-18, 01/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. Pilling, D. Roife, M. Wang, S. D. Ronkainen, J. R. Crawford, E. L. Travis, and R. H. Gomer Reduction of Bleomycin-Induced Pulmonary Fibrosis by Serum Amyloid P J. Immunol., September 15, 2007; 179(6): 4035 - 4044. [Abstract] [Full Text] [PDF]

				S. Ghosh, T. Mendoza, L. A. Ortiz, G. W. Hoyle, C. D. Fermin, A. R. Brody, M. Friedman, and G. F. Morris Bleomycin Sensitivity of Mice Expressing Dominant-Negative p53 in the Lung Epithelium Am. J. Respir. Crit. Care Med., September 15, 2002; 166(6): 890 - 897. [Abstract] [Full Text]

				L. A. Ortiz, J. A. Lasky, H. Safah, M. Reyes, A. Miller, G. Lungarella, and M. Friedman Exacerbation of bleomycin-induced lung injury in mice by amifostine Am J Physiol Lung Cell Mol Physiol, December 1, 1999; 277(6): L1239 - L1244. [Abstract] [Full Text] [PDF]

				L. A. Ortiz, K. Moroz, J.-Y. Liu, G. W. Hoyle, T. Hammond, R. F. Hamilton, A. Holian, W. Banks, A. R. Brody, and M. Friedman Alveolar macrophage apoptosis and TNF-alpha , but not p53, expression correlate with murine response to bleomycin Am J Physiol Lung Cell Mol Physiol, December 1, 1998; 275(6): L1208 - L1218. [Abstract] [Full Text] [PDF]